About US
Contact us
-
GlaxoSmithKline, Theravance tout new data on COPD drugsIn the race for new COPD drugs, GlaxoSmithKline ($GSK) and Theravance ($THRX) have released new data from a slew of late-stage studies of their LAMA/LABA combo for COPD. The key finding is that their2012/7/3
-
Pharma gets what it bargained for in Supreme Court rulingAlong with the Supreme Court's decision that, for the most part, the Affordable Healthcare Act is constitutional has come a firestorm of analysis of what it means to drug companies going forward: more2012/7/2
-
India to begin paying for drugs for 'everyone'It looks like the pharma industry may have gotten through to the government in India about the need to expand public access to healthcare. Currently,Indian patients needing healthcare, including drugs2012/7/2
-
• GSK chief: Europe's woes may slice pharma prices by 6%European price cuts are taking an even bigger bite out of GlaxoSmithKline's ($GSK) sales than CEO Andrew Witty had expected--and he expected a sizable one.2012/6/28
-
NICE says yes to Tarceva, Zytiga, Botox, no to Herceptin, TyverbIt was three yeas and two nays from the National Institutes of Health and Clinical Excellence today. Allergan ($AGN) got approval for a new use for Botox, Johnson & Johnson's ($JNJ) Janssen unit2012/6/28
-
Roche slashes 1,000 jobs in closure of Nutley R&D siteIn a major restructuring of its global R&D operations, Roche has just announced that it is closing its sprawling center in Nutley, NJ, axing 1,000 staffers and redistributing research activities i2012/6/27
-
FDA official: Amylin held back safety data on ByettaThe FDA says Amylin Pharmaceuticals hasn't been completely honest about its diabetes drugs. Actually, a top agency official said so back in January, but the documents were only just posted to the FDA2012/6/27
-
Witty: E.U. can avert drug-supply disaster in S. EuropeIs there a way out of the drug-supply mess in cash-strapped European countries? Pharma leaders think so. In a letter to European Union officials, GlaxoSmithKline ($GSK) CEO Andrew Witty urged them to2012/6/26
-
Regulatory headaches replace patent pain, KPMG findsIf there is any benefit to be found by pharma executives in the tightening grip of Congress and regulators that they perceive, it might be that it has taken their minds off patent losses. Or so the la2012/6/26
-
As compulsory licensing spreads, drugmakers adaptThere is the concept associated with evolution that you must adapt or die. Now some experts are suggesting the same thing for drugmakers when it comes to the growing threat of compulsory licensing. N2012/6/25